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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome that is
closely associated with multiple factors such as obesity, hyperlipidemia and type 2 diabetes mellitus. However,
other risk factors for the development of NAFLD are unclear. With the association between periodontal disease and
the development of systemic diseases receiving increasing attention recently, we conducted this study to
investigate the relationship between NAFLD and infection with Porphyromonas gingivalis (P. gingivalis), a major
causative agent of periodontitis.
Methods: The detection frequencies of periodontal bacteria in oral samples collected from 150 biopsy-proven
NAFLD patients (102 with non-alcoholic steatohepatitis (NASH) and 48 with non-alcoholic fatty liver (NAFL)
patients) and 60 non-NAFLD control subjects were determined. Detection of P. gingivalis and other
periodontopathic bacteria were detected by PCR assay. In addition, effect of P. gingivalis-infection on mouse
NAFLD model was investigated. To clarify the exact contribution of P. gingivalis-induced periodontitis, non-surgical
periodontal treatments were also undertaken for 3 months in 10 NAFLD patients with periodontitis.
Results: The detection frequency of P. gingivalis in NAFLD patients was significantly higher than that in the non-
NAFLD control subjects (46.7% vs. 21.7%, odds ratio: 3.16). In addition, the detection frequency of P. gingivalis in
NASH patients was markedly higher than that in the non-NAFLD subjects (52.0%, odds ratio: 3.91). Most of the
P. gingivalis fimbria detected in the NAFLD patients was of invasive genotypes, especially type II (50.0%). Infection
of type II P. gingivalis on NAFLD model of mice accelerated the NAFLD progression. The non-surgical periodontal
treatments on NAFLD patients carried out for 3 months ameliorated the liver function parameters, such as the
serum levels of AST and ALT.
Conclusions: Infection with high-virulence P. gingivalis might be an additional risk factor for the development/
progression of NAFLD/NASH.
Keywords: Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), P. gingivalis, Oral bac-
teria, Insulin resistance
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Almost one-quarter of the adults in the world popula-
tion show excessive hepatic fat accumulation, and
non-alcoholic fatty liver disease (NAFLD) is the most
common form of chronic liver disease encountered in
many industrialized countries [1,2]. NAFLD represents a
wide spectrum of conditions ranging from non-alcoholic
fatty liver (NAFL) to non-alcoholic steatohepatitis
(NASH) [1-3]. The former generally shows a non-pro-
gressive clinical course, while the latter is a more serious
form of NAFLD and may progress to cirrhosis or end-
stage liver disease [1-6]. Many risk factors for the devel-
opment of NAFLD have been proposed, such as obesity,
diabetes, insulin resistance, oxidative stress and inflam-
mation [1-6]. However, it is still unclear whether other
risk factors may also be involved in the pathogenesis
and progression of NAFLD. In addition, the factors
involved in the progression of NAFL to NASH are also
not fully understood. Therefore, identification of factors
responsible for the progression of NASH would be help-
ful in the prevention and designing of strategies for the
treatment of NASH.
Chronic marginal periodontitis occurs worldwide and
is among the most prevalent of microbial diseases in
humans [7]. Periodontal inflammation often leads to
superficial ulcers on the gingival sulcus, where blood
capillaries are exposed to microbial biofilms [8]. It is well
known that periodontal pathogens are translocated and
released from the sulcus into the bloodstream, and such
transient bacteremia has been demonstrated in clinical
trials to occur after preventive dental procedures and
periodontal therapy, including tooth brushing, chewing,
subgingival irrigation, periodontal treatment, and dental
extractions, at reported frequencies ranging from 17% to
100% in infected individuals [9-11]. Porphyromonas gingi-
valis (P. gingivalis) is well known as a major causative
agent of periodontitis [12-14]. Recent reports suggest
that infection with P. gingivalis is associated with several
systemic diseases, including cardiovascular diseases, pre-
term low birth weight, rheumatoid arthritis, and diabetes
mellitus (DM) [12-14]. However, there are no reports
until date concerning the involvement P. gingivalis infec-
tion in the pathogenesis and progression of NAFLD.
Therefore, we conducted this retrospective observational
study to investigate the relationship between NAFLD and
infection with P. gingivalis.
Methods
Patients and control subjects
This study was conducted with the approval of the
Ethics Committees of Yokohama City University, Osaka
University, and Nara City Hospital. A total of 150 Japa-
nese NAFLD patients (102 with NASH and 48 with
NAFL) and 60 control subjects (non-NAFLD) from
similar socioeconomic strata were recruited. After provi-
sion of adequate explanation, written informed consent
for participation in this study was obtained from all the
subjects prior to the sample collections. All control sub-
jects (non-NAFLD) were confirmed to have normal liver
function (aspartate aminotransferase (AST), alanine ami-
notransaminase (ALT) levels within normal range), no
evidence of viral hepatitis and no evidence of the pre-
sence of criteria of the metabolic syndrome, such as dia-
betes mellitus and high serum cholesterol (see Table 1).
They were also confirmed to not have a history of habi-
tual alcohol drinking-in this context, all subjects with a
history of excessive alcohol consumption (> 20 g/day)
were excluded. Other exclusion criteria for NAFLD
patients were a history of use of drugs associated with
fatty liver diseases and a history of other hepatic dis-
eases, such as chronic hepatitis C, hepatitis B (serum
positive for hepatitis B surface antigen), autoimmune
hepatitis, primary biliary cirrhosis (PBC), sclerosing cho-
langitis, hemochromatosis, alpha-antitrypsin deficiency,
Wilson’s disease, hepatic injury caused by substance
abuse [15-18]. None of the patients had any clinical
Table 1 Summary of the data of the NAFLD and healthy
subjects
Healthy
(n = 60)
NAFLD
(n = 150)
P value
Age (mean ± SE) 52.9 ± 2.4 54.6 ± 1.2 0.4609
Gender (M : F) 29 : 31 64 : 86 0.5387
AST (mean ± SE) 20.7 ± 0.6 49.0 ± 2.3 < 0.0001
ALT (mean ± SE) 18.3 ± 0.9 70.1 ± 3.6 < 0.0001
DM (Y : N) 0 : 60 35 : 105 < 0.0001
Histopathological Findings
Steatosis
1N A 5 3
2N A 5 7
3N A 4 0
Inflammation
0N A 2 8
1N A 9 7
2N A 2 2
3N A 3
Ballooning
0N A 5 0
1N A 5 2
2N A 4 8
Fibrosis
0N A 4 9
1N A 5 4
2N A 2 4
3N A 1 9
4N A 4
DM: with (Y) or without (N) diabetes mellitus. NA: not applicable for biopsy.
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phalopathy, ascites, variceal bleeding, or elevation of the
serum bilirubin level to more than twofold the upper
limit of normal [15-17].
Pathology
Liver specimens were obtained from NAFLD patients for
the purpose of diagnosis and staging for NASH, with an
18-gauge needle biopsy apparatus (Pro-Mag, Medical
Device Technologies, Gainsville, FL, USA). In our present
study, 102 were NASH and 48 were NAFL (non-alcoholic
fatty liver). On NASH patients, their ALT/AST levels
were much increased and other many abnormal symp-
toms were observed. So, all of NASH patients were
applied the biopsy. Among the 48 NAFL patients, 36
cases showed the abnormal ALT/AST levels, and other
abnormal symptoms were observed. Therefore, they were
also applied the biopsy. Other 12 NAFL patients, their
ALT levels were almost normal range. It was reported
that the patients of NAFLD with normal ALT level may
also have histological features at risk for disease progres-
sion [19-21]. Therefore, we performed liver biopsy for
the purpose of diagnosing and staging for NASH,
although the ALT level was in normal range. However,
the case of application for the biopsy was strictly defined
b yt h ec r i t e r i af o l l o w s ;T h eN A F L Dp a t i e n t sw e r es u s -
pected that 1) the existence of severe steatosis (such as
persist evidence of severe steatosis at ultrasonography
and/or CT) or 2) the fibrosis was progressed (such as pla-
telet count was low and/or serum albmin was low and/or
the hyaluronic acid was high and/or the type IV collagen
7s domain was high and/or the liver stiffness was high by
transient elastography). In fact, the 12 NAFL patients
were fit the cases described above. We excluded unclear
borderline cases in this study, because they were not per-
formed the biopsy. Therefore, total 150 NADLF patients
(102 NASH + 36 abnormal ALT/AST-NAFL + 12 normal
ALT/AST-NAFL) were applied the biopsy.
We did not perform any biopsies on control subjects,
because their ALT/AST levels are normal and they have
no abnormal symptoms.
The biopsy specimens were obtained from the same
lobe to enable obtainment of a sufficient sample size for
analysis, and stained with hematoxylin-eosin, reticulin,
and Masson trichrome stains. The histopathological
findings were evaluated and confirmed as NAFLD/
NASH according to the criteria of Matteoni et al. [15].
The criterion for the diagnosis of NAFLD was; macrove-
sicular steatosis affecting at least 5% of the hepatocytes,
with the cases being further classified as steatosis or
steatohepatitis. In addition to the presence of steatosis,
the minimum criteria for the diagnosis of steatohepatitis
included the presence of lobular inflammation and
either ballooning of cells or perisinusoidal/pericellular
fibrosis in zone 3 of the hepatic acini [15]. The degree
of steatosis was assessed as follows, based on the per-
centage of hepatocytes containing macrovesicular fat
droplets: grade 0, no steatosis; grade 1, < 33% hepato-
cytes containing macrovesicular fat droplets; grade 2,
33%-66% hepatocytes containing macrovesicular fat dro-
plets; grade 3, > 66% hepatocytes containing macrovesi-
cular fat droplets. The severity of the necroinflammatory
activity was assessed as follows: grade 1, occasional bal-
looned hepatocytes (mainly zone 3), scattered intraaci-
nar neutrophils ± lymphocytes, no or mild portal
inflammation; grade 2, obvious ballooning degeneration
in zone 3, intra-acinar neutrophils, mild to moderate
portal and intra-acinar inflammation; grade 3, wide-
spread ballooning, intra-acinar inflammation, accumula-
tion of neurtophils near the ballooned hepatocytes, mild
to moderate portal inflammation [15-18].
Clinical and laboratory evaluation
Blood samples were obtained from the patients after
overnight fasting (12 h) for measurement of the serum
levels of AST, ALT, gamma glutamyltranspeptidase
(GGT), choline esterase, albumin, triglyceride, high den-
sity lipoprotein (HDL) cholesterol, low density lipopro-
tein (LDL) cholesterol, iron, ferritin, insulin, type IV
collagen 7s and hyaluronic acid (HA) concentration,
fasting blood glucose, and hematological parameters,
including the red blood cell count, hematocrit, and
hemoglobin. Serum insulin levels were measured by
radioimmunoassay.
Other laboratory biochemical parameters were mea-
sured with a conventional automated analyzer. IR was
calculated by the modified homeostasis model assess-
ment of insulin resistance (HOMA-IR) using the for-
mula: HOMA-IR = fasting insulin (lU/ml) × plasma
glucose (mg/dl)/405 [22].
Detection of P. gingivalis and other periodontopathic
bacteria from saliva samples
The specimens were processed for PCR assay using a pre-
viously reported method [23]. Briefly, bacterial cells were
collected in micro-centrifuge tubes after centrifugation of
500 μl of saliva at 16,000 × g for 5 min. Next, 80 μlo fa
nuclear lysis buffer (Promega, Madison, WI, USA) was
added, and the mixture was incubated at 80°C for 5 min,
followed by the addition of 60 μl of protein precipitation
solution (Promega). The proteins were removed by centri-
fugation at 16,000 × g for 3 min, and the DNA was purified
by phenol-chloroform extraction and ethanol precipitation.
The extracted DNA was then dissolved in 50 μlo fT Eb u f -
fer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]).
First, we confirmed the appropriate extraction of DNA
by PCR using a ubiquitous primer set (5’-AGA GTT
TGA TCC TGG CTC AG-3’ and 5’-GGC TAC CTT
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detected using a PCR method with a P. gingivalis-speci-
fic primer set (5’-TGT AGA TGA CTG ATG GTG
AAA ACC-3’ and 5’-ACG TCA TCC CCA CCT TCC
TC-3’), as described previously [24]. P. gingivalis-positive
specimens were further analyzed to differentiate among
their fimA genotypes using a PCR method with specific
primer sets for each fimA type as previously reported
[23,25,26]. Genomic DNA samples extracted from
P. gingivalis strains ATCC33277 (type I), OMZ314 (II),
6/26 (III), HG564 (IV), HNA99 (V), and HG1691 (Ib)
were used as positive controls.
Detection of other periodontal bacteria, such as Trepo-
nema denticola, Prevotella intermedia, Tannerella forsythia,
Aggregatibactor actinomycetemcomitans, Campyrobacter
rectus, was also performed according to a previously
d e s c r i b e dm e t h o d[ 2 7 ] .
Animal experiment
A l la n i m a le x p e r i m e n t si nt h ep r e s e n ts t u d yc o n f o r m e d
to the Guide for the Care and Use of Laboratory Ani-
mals published by the United States National Institutes
of Health, and were approved by the institutional animal
care and use committees of Osaka University Graduate
School of Dentistry.
Mouse NAFLD model was produced according to the
method described previously [28]. Briefly, C57BL/6J mice
(6 weeks old, Charles River Japan, Tokyo) allowed free
access to water and food throughout experimental period.
Mice were randomly divided three groups, High-fat diet
control (HFD control); High-fat diet plus P. gingivalis
(HFD + P.g); and Basal diet plus P. gingivalis (Basal diet +
P.g), respectively. HFD groups were administered High-fat
diet 32 (Japan CLEA, Tokyo); this feed contains 506.8
kcal/100 g (57.5% from fat, 19.7% from protein, and 22.8%
from carbohydrate). Basal diet group was administered
basal diet (ORIENTAL YEAST Co., Ltd., Tokyo); this feed
contains 360 kcal/100 g (13.3% from fat, 26.2% from pro-
tein, and 60.5% from carbohydrate). Four weeks after the
start of HF or basal diet, mice were administered P. gingi-
valis (OMZ314 strain, 10
7 cells/body) or vehicle via jugu-
lar vein. Because of the high-frequency of type II fimA
detection in NAFLD patients, we selected the OMZ314
strain (Type II fimA) for the administration to mice.
Twelve weeks after the start of HF or basal diet, body
weight, liver weight, and pathological observations were
performed.
Periodontal treatments
We randomly selected 10 NAFLD patients who were also
suffering from periodontitis associated with P. gingivalis.
We prospectively evaluated the efficacy of consecutive per-
iodontal treatments on the amelioration of NAFLD. After
provision of adequate explanation, written informed
consent was obtained from all the patients prior to their
entry into this study. This trial was registered with the
University Hospital Medical Information Network
(UMIN) Clinical Trial Registry (No. UMIN000004281).
The inclusion criteria for patients with chronic period-
ontitis were patients who had not received any periodontal
therapies within the previous six months or any anti-
microbial therapies within the three months prior to the
baseline examination, and had at least 10 residual teeth.
All of the patients had a PD of greater than 5 mm in at
least four tooth regions. Then, oral hygiene instructions
were provided to each patient, followed by scaling and
root planing procedures, and then application of minocy-
cline hydrochloride. These treatment procedures were
continued for 3 months, and the periodontal conditions
improved with the treatment. In our previous therapy of
periodontal treatments similar to this study, more than
95% of decrease in P. gingivalis in oral samples was
confirmed.
The patients did not receive any medication for the
treatment of impaired liver function, metabolic syn-
drome or NAFLD during the 3-month periodontal treat-
ment period.
Statistical analysis
Statistical analyses were performed using the SPSS for
Windows, ver. 12. Results are expressed as mean ± SEM.
Statistical comparisons were made using the Student’s
t-test or Scheffe’s method after analysis of variance
(ANOVA). Differences were considered to be significant
at < 0.05. In addition, multiple regression analysis was per-
formed in the NAFLD patients and control subjects with
P. gingivalis infection to identify the predictive value of
P. gingivalis infection for the development/progression of
NFLD, using demographic factors such as the age, history
of DM and BMI.
Results
Frequency of infection with periodontal pathogenic
bacteria in NAFLD/NASH patients
The detection frequency of P. gingivalis infection in
the NAFLD patients and control subjects are shown in
Table 1. As shown in Figure 1A, the detection frequency
of P. gingivalis in the NAFLD patients was 46.7%, being
significantly higher than that in the non-NAFLD control
(healthy) subjects (21.7%; odds ratio: 3.16). Similarly, the
detection frequency of T. denticola in the NAFLD
patients was significantly higher than that in the control
subjects (34.7% vs. 16.7%; odds ratio: 2.65). Interestingly,
the detection frequency of P. gingivalis in the patients
with NASH was also markedly higher than that in the
non-NAFLD control subjects (52.0%; odds ratio: 3.91, in
Figure 1B). In contrast, no significant differences in the
detection frequency of any other bacterial species were
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(data not shown).
Multiple regression analysis to identify predictive factors
for the development/progression of NAFLD
To clarify the relationship between NAFLD and P. gingi-
valis infection, multiple regression analysis was per-
formed for the NAFLD patients and the control subjects
using demographic factors such as the age, history of
DM and BMI. The result revealed a statistically signifi-
cantly higher prevalence of P. gingivalis infection in
N A F L Dp a t i e n t sa sc o m p a r e dw i t ht h a ti nt h ec o n t r o l
subjects, even after adjusting for age, history of DM and
BMI (Table 2). This result suggests that the presence of
P. gingivalis infection might be an independent predictor
of the development of NAFLD.
Comparison of various parameters between P. gingivalis-
positive and P. gingivalis-negative NAFLD patients
As shown in Table 3, comparative analysis of various
parameters was conducted between P. gingivalis-positive
and P. gingivalis-negative NAFLD patients. No significant
differences in the serum ALT, AST, gGTP, TG, HDL,
LDL, Fe, FPG, IRI, HA or type-IV collagen 7S were
observed between the two groups of patients. However, a
tendency towards decrease of the serum levels of gGTP,
TG, cholinesterase, Fe and ferritin was observed in the
P. gingivalis-positive patients. In addition, significant
decrease of the serum albumin was also observed in this
group. Similar results were observed in the P. gingivalis-
positive and -negative patients with NASH. On the other
hand, a significant difference in the prevalence of DM
was observed between the P. gingivalis-positive and
-negative groups among patients with NASH, while no
such difference was observed between the two groups
among NAFLD patients.
Analysis of P. gingivalis fimbriae
P. gingivalis fimbriae, filamentous appendages on the
bacterial surface, are classified into 6 genotypes based
on the diversity of the fimA genes encoding each fim-
brial subunit. It has been demonstrated that bacterial
clones with types II, IV or Ib fimA are invasive, whereas
those with types I, III or V fimbriae are non-invasive
[23,25,26]. Interestingly, most of the fimA genotypes
detected in the P. gingivalis-positive specimens were of
t h ei n v a s i v et y p e s ;I I( 5 0 . 0 % ) ,I V( 1 4 . 3 % ) ,I b( 3 0 . 0 % ) ;
total, 94.3% (Figure 2). These results suggest that inva-
sive-type P. gingivalis m a yb ei n v o l v e di nt h ep r o g r e s -
sion of NAFLD.
Acceleration of NAFLD in HFD-mice infected with P.
gingivalis: Analysis of mouse NAFLD model
In our HFD-induced mouse NAFLD model, accumula-
tion of lipid in liver and marked increase in body weight
are usually observed at 24 weeks, but slight at 12 weeks,
after the start of HFD [28]. However, in this study, we
compared body weight, liver weight, and pathological
findings between P. gingivalis- and vehicle-administered
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Figure 1 Detection frequency of P. gingivalis in NAFLD/NASH
patients and control (non-NAFLD) subjects. A: Comparison of
the detection frequency of P. gingivalis between NAFLD patients
and non-NAFLD (control) subjects. B: Comparison of the detection
frequencies of P. gingivalis among NASH patients, non-alcoholic
fatty liver (NAFL) patients and in non-NAFLD (control) subjects. OR:
odds ratio, CI: confidence interval.
Table 2 Multiple regression analysis to identify predictive
factors for the development/progression of NAFLD
Risk Factors standard error Odds ratio P value 95% CI
P. gingivalis 0.490 2.615 0.049 1.001-6.832
Age 0.014 0.994 0.668 0.968-1.021
DM 0.821 9.433 0.006 1.883-47.62
BMI 0.085 1.631 < 0.0001 1.381-1.927
The dependent variable is presence of NAFLD, and the independent variables
are presence/absence of P. gingivalis infection, age, presence/absence of
diabetes (DM), and body mass index (BMI). P value < 0.05 were considered
significant. R2 for entire model = 0.429.
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As shown in Figure 3, the mice of HFD control group
showed the slight increase in body and liver weight
(Figure 3A and 3B, right panels). In contrast, the mice
of HFD + P.g group showed the marked increase in
body and liver weight. Obvious differences of whole
body and liver between HFD control and HFD + P.g
group were observed (Figure 3A and 3B, left panels). In
contrast, administration of Streptococcus mutans,m a j o r
caries pathogen but non-periodontitis-related oral bac-
teria, did not show any increases in body (33.50 + 2.51
g on bacteria vs. 36.33 + 3.21 g on control, P = 0.9325)
and liver weight (1.27 + 0.15 g on bacteria vs. 1.38 +
0.13 g on control, P = 0.3811). In addition, other non-
virulent oral bacteria, such as Streptococcus sanguinis
and Streptococcus salivalius, did not show the increases
in body and liver weights (data not shown). These
results indicate that the effect of marked increase in
body and liver weight might be P. gingivalis-specific
phenomena. On the pathological observations, marked
accumulation of lipid was observed in the mice infected
with P. gingivalis (Figure 3C, middle panel). Further-
more, the marked increases in ALT level and liver tri-
glyceride level were also observed (Figure 3D). These
results indicate that the infection of P. gingivalis on
HFD condition accelerates the progression of NAFLD.
Improvement of liver functions by the periodontal
treatments in NAFLD patients with periodontitis
To clarify the possibility that periodontal treatments in
NAFLD patients with periodontitis may improve the
condition of NAFLD, we applied the periodontal treat-
ments to randomly selected NAFLD patients. A ten-
dency towards decrease of the serum AST and ALT
Table 3 Comparison of various parameters between P.gingivalis (+) and (-) NASH and NAFL patients
NASH
(n = 102)
NAFL
(n = 48)
P.gingivalis P.gingivalis P values P.gingivalis P.gingivalis P values
(+) (-) (+) (-)
(n = 53) (n = 49) (n = 17) (n = 31)
AST (IU/L) 54.8 ± 4.9 54.8 ± 3.7 0.9994 32.1 ± 2.8 39.1 ± 3.1 0.1410
ALT (IU/L) 72.9 ± 6.9 78.9 ± 5.9 0.5179 47.6 ± 6.3 63.8 ± 7.3 0.1472
gGTP (IU/L) 74.0 ± 8.2 71.8 ± 7.8 0.8479 62.1 ± 9.9 116.3 ± 22.7 0.0930
ChoE (IU/L) 357.9 ± 12.0 383.9 ± 13.5 0.1537 397.3 ± 14.7 377.3 ± 12.6 0.3267
Albumin (g/dl) 4.35 ± 0.05 4.50 ± 0.05 0.0488* 4.25 ± 0.09 4.58 ± 0.06 0.0017*
TG (mg/dl) 161.3 ± 11.8 162.4 ± 9.4 0.9246 163.6 ± 21.7 161.5 ± 12.1 0.9293
HDL (mg/dl) 60.2 ± 3.1 54.8 ± 3.1 0.2190 57.0 ± 3.3 58.7 ± 3.4 0.7470
LDL (mg/dl) 122.9 ± 4.0 124.3 ± 5.2 0.8295 132.2 ± 7.9 129.5 ± 5.2 0.7720
Ferritin (ng/ml) 203.8 ± 22.4 276.4 ± 32.4 0.0646 178.6 ± 30.9 211.1 ± 32.2 0.5203
Fe (ng/ml) 110.2 ± 6.5 130.7 ± 11.5 0.1241 107.2 ± 9.6 117.0 ± 8.1 0.4636
FPG (mg/dl) 133.6 ± 25.4 121.9 ± 9.6 0.6483 112.5 ± 7.0 133.7 ± 17.5 0.4282
IRI (μU/ml) 15.1 ± 1.8 15.6 ± 1.6 0.8397 9.5 ± 1.5 11.0 ± 2.1 0.7461
DM (Y:N) 17:36 7:42 0.0386* 5:12 6:25 0.4856
HA (ng/ml) 68.9 ± 11.1 52.3 ± 7.2 0.2178 43.3 ± 15.1 34.2 ± 5.9 0.5046
IV collagen 7S (mg/ml) 5.32 ± 0.22 5.00 ± 0.18 0.2632 3.62 ± 0.17 3.84 ± 0.17 0.2454
DM: with (Y) or without (N) diabetes mellitus
Type II
(50.0%) Type Ib
(30.0%)
Type IV
(14.3%)
Type III
(5.7%)
Figure 2 Percentage of detection frequency of various fimA types
on NAFLD patients.M o s to ft h efimA genotypes detected in the P.
gingivalis-positive specimens were of the invasive types; II (50.0%), IV
(14.3%), Ib (30.0%); total, 94.3%. Type III (5.7%) is non-invasive type.
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Figure 3 Effect of administration of P. gingivalis on mouse NAFLD model. A: Typical pictures of whole body (left panel) and body weight
(right panel) of mice administered vehicle (HFD control) or P. gingivalis (HFD + P.g) under the high fat diet (HFD) condition. Each column
represents mean + SEM from 12 to 13 independent animals. **; P < 0.01. B: Typical pictures of liver (left panel) and liver weight (right panel) of
mice administered vehicle (HFD control) or P. gingivalis (HFD + P.g) under the high fat diet (HFD) condition. Each column represents mean +
SEM from 12 to 13 independent animals. **; P < 0.01. C: Typical pathological pictures of liver of mice administered vehicle (HFD control) or P.
gingivalis (HFD + P.g) under the high fat diet (HFD) condition, or P. gingivalis under basal diet condition (Basal diet + P.g). Each column
represents mean + SEM from 12 to 13 independent animals. **; P < 0.01. D: Alterations of ALT/AST levels and liver triglyceride level. Each
column represents mean + SEM from 6 to 9 independent animals. *; P < 0.05 and **; P < 0.01, respectively.
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Page 7 of 10levels with periodontal treatments was observed by 1
month after the start of the treatment procedures
(Figure 4). At the period of 2 months of treatments, sig-
nificant decreases of both serum AST and ALT levels
were observed as compared with the levels at the base-
line (P = 0.0165, and P = 0.0031, respectively). Further
improvements of the serum AST and ALT levels were
observed at the end of 3 months after the start of the
treatment procedures (P = 0.0069, and P = 0.0009,
respectively). There were no changes in body weights
during the treatment period.
Discussion
Many factors have been implicated in the pathogenesis
of NAFLD/NASH, including obesity, insulin resistance,
oxidative stress and mitochondrial dysfunction [1-6].
Recently, the association between low vitamin D level
and NAFLD has also been reported [29]. However, it is
still unclear whether any other factors might be involved
in the pathogenesis and progression of NASH in its
common form. Therefore, identifying the mechanisms
responsible for the progression of NASH may be useful
for designing therapeutic strategies for these diseases.
In the present study, we showed that the prevalence of
P. gingivalis infection was significantly higher in the
NAFLD patients than in the healthy subjects. This result
suggests that P. gingivalis infection may be involved in
the mechanism of onset of NAFLD, because P. gingivalis
itself or the endotoxin and cytokines released from the
bacteria can easily enter the blood circulation. Multiple
regression analysis in NAFLD patients and control sub-
jects to identify the predictive value of P. gingivalis infec-
tion for the development of NAFLD using demographic
factors such as the age, history of DM and BMI revealed
a significantly higher prevalence of P. gingivalis infection
in NAFLD patients as compared with that in control sub-
jects, even after adjusting for age, history of DM and
BMI. This result suggests that P. gingivalis infection may
be an independent risk factor for NAFLD.
A relationship has been reported between infection
with periodontal bacteria and the onset of type 2 diabetes
mellitus [30,31]. Namely, it is considered that the
increased serum levels of lipopolysaccharide and TNF-a
associated with P. gingivalis infection induce insulin
resistance, leading to the development of type 2 diabetes
[30,31]. In addition, our colleagues reported relationship
between the fimbrial type of the periodontal bacteria
causing periodontitis and the risk of development of type
2 diabetes mellitus [32]. In fact, most NAFLD patients
with P. gingivalis infection show bacteria with invasive
t y p e so ff i m b r i a ,s u c ha sI I ,I V ,a n dI b .T h e r e f o r e ,i ti s
suggested that the high detection frequency of P. gingiva-
lis in NAFLD patients may be due to the presence of
coexisting DM, based on the correlation between
NAFLD and DM. However, in the present study, no sig-
nificant difference in the frequency of DM was noted
between P. gingivalis-positive and -negative groups
among the NAFLD patients (Table 3). Therefore, it is
suggested that the high detection frequency of P. gingiva-
lis in NAFLD patients was not due to coexisting DM in
our study. In contrast, a statistically significant difference
in the frequency of DM was noted between the P. gingi-
valis-positive and -negative NASH patients. These results
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Figure 4 Improvement of the serum AST and ALT levels with
periodontal treatments in NAFLD patients with periodontitis.
Box plots represent the inter-quartile range (boxes), median (central
horizontal lines), range (thin lines) and outliers (circles) of the serum
AST or ALT levels from 10 cases. Stepwise decreases of the serum
AST (P < 0.0001, Kruskal-Wallis test) and ALT (P < 0.0001, Kruskal-
Wallis test) were observed during the course of the periodontal
treatments.
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Namely, both DM and P. gingivalis infection may coop-
eratively increase the risk of progression from NAFL to
NASH. In fact, the high detection frequency of P. gingiva-
lis infection in NASH patients was more obvious than
that in the NAFL patients.
In comparison between P. gingivalis-positive and nega-
tive NASH/NAFLD patients, statistically significant
decrease in serum albumin level was observed. These
results indicate that decrease in liver function may be
accelerated in P. gingivalis-positive patients. In addition,
the tendency, but not significant, of increases in hyaluro-
nic acid and IV collagen 7S levels were also observed. As
those are indices of the progression of liver fibrosis, it
may be hypothesized that liver fibrosis and decrease in
function might be accelerated in P. gingivalis-positive
patients, although the destroy of liver is not so marked.
Thus, infection with P. gingivalis may be one of the risk
factors for not only the second stage of progression to
NASH, but also the first stage of the pathogenesis for
NAFL. In fact, the infection of type II P. gingivalis on
NAFLD mouse model dramatically accelerated the
NAFLD progression without any other additional treat-
ments such as choline-deficient, l-amino acid-defined
diet-fed [33] or LDL receptor knockout [34]. The
NAFLD progression on P. gingivalis-infected mice was
markedly faster than that on control mice under the
HFD condition, but not basal diet condition (see Figure
3C, right panel). These results clearly indicate that both
HFD condition and P. gingivalis infection cooperatively
increase the risk of pathogenesis of NAFLD. As the infec-
tion of other oral bacteria on NAFLD model did not
accelerate the progression to NAFLD, the acceleration of
NAFLD progression by P. gingivalis under HFD condi-
tion might be high-virulence P. gingivalis-specific effect.
Further animal experiments will be required.
The mechanism of P. gingivalis-mediated the patho-
genesis of NAFLD/NASH is unclear. The current model
of NASH pathogenesis proposes two stages of progres-
sion. First, insulin resistance causes lipid accumulation in
the hepatocytes; second, cellular insults, such as oxidative
stress, lipid toxicity, mitochondrial dysfunction, and/or
bacterial endotoxins from the gut cause hepatic inflam-
mation, resulting in the development of NASH [1-6]. In
fact, administration of lipopolysaccharide (LPS) showed
the NASH-like conditions in HFD mice (unpublished
data). Because the infection with high-virulence strains of
P. gingivalis may generate a large amount of lipopolysac-
charide and TNF-a, it may result in inflammation of not
only the local gingiva, but also involve other systemic
organs [23,25,30,31]. Such inflammatory mediators are
involved in insulin resistance. In addition, P. gingivalis
can easily invade the blood circulation from the gingiva
after several periodontal procedures/processes, including
tooth brushing, chewing, subgingival irrigation, and den-
tal extractions [9-11]. These reports support our conclu-
sions that infection with P. gingivalis may be one of the
risk factors for the development of NAFLD/NASH.
We also confirmed the efficacy of the periodontal
treatments in improving liver function parameters such
as serum AST and ALT in NAFLD patients (Figure 4).
This result indicates that periodontitis caused by P. gin-
givalis in NAFLD patients may be a risk factor for the
aggravation of NAFLD, and that periodontal treatments
may be useful supportive measures in the management
of patients with NAFLD. Further large scale clinical
practice for the periodontal treatments in NAFLD
patients will be required in future.
Conclusions
In conclusion, P. gingivalis infection was noted at a sig-
nificantly high frequency in NAFLD/NASH patients.
Infection of type II P. gingivalis on NAFLD mouse
model accelerated the NAFLD progression. Also, the
effectiveness of periodontal treatments in ameliorating
the severity of NAFLD was observed. Thus, infection
with high-virulence P. gingivalis may be a risk factor for
the development/progression of NAFLD/NASH.
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